%0 Journal Article
%T Atezolizumab-Induced Stevens-Johnson Syndrome in a Patient with Non-Small Cell Lung Carcinoma
%A Pamela Chayavichitsilp
%A Phatcharawat Chirasuthat
%J Archive of "Case Reports in Dermatology".
%D 2018
%R 10.1159/000492172
%X Atezolizumab is a humanized anti-PD-L1 immune checkpoint antibody that is currently used in many kinds of advanced carcinoma including metastatic non-small cell lung cancer. The cutaneous side effect profile reported only 20$ of the patients which had only mild maculopapular rash that required no treatment. There is no case report of anti-PD-L1 antibody-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) eruptions. To the best of our knowledge, there is no case report of atezolizumab-induced SJS or SJS/TEN induced by anti-PD-L1 immune checkpoint antibodies. We believe that our report will be useful to dermatologists who are consultants in the inpatient settings, as atezolizumab is an anti-neoplastic agent that has a potential to be used in multiple malignancies
%K Drug eruption
%K Drug hypersensitivity syndrome
%K Stevens-Johnson syndrome
%K Lung cancer
%K Lung cancer treatment
%K Cancer
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120418/